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Abstract
Introduction: While some targeted agents should not be used in squamous cell carcinomas (SCCs), other agents might
preferably target SCCs. In a previous microarray study, one of the top differentially expressed genes between
adenocarcinomas (ACs) and SCCs is P63. It is a well-known marker of squamous differentiation, but surprisingly, its
expression is not widely used for this purpose. Our goals in this study were (1) to further confirm our microarray data, (2) to
analize the value of P63 immunohistochemistry (IHC) in reducing the number of large cell carcinoma (LCC) diagnoses in
surgical specimens, and (3) to investigate the potential of P63 IHC to minimize the proportion of ‘‘carcinoma NOS (not
otherwise specified)’’ in a prospective series of small tumor samples.
Methods: With these goals in mind, we studied (1) a tissue-microarray comprising 33 ACs and 99 SCCs on which we
performed P63 IHC, (2) a series of 20 surgically resected LCCs studied for P63 and TTF-1 IHC, and (3) a prospective cohort of
66 small thoracic samples, including 32 carcinoma NOS, that were further classified by the result of P63 and TTF-1 IHC.
Results: The results in the three independent cohorts were as follows: (1) P63 IHC was differentially expressed in SCCs when
compared to ACs (p,0.0001); (2) half of the 20 (50%) LCCs were positive for P63 and were reclassified as SCCs; and (3) all
P63 positive cases (34%) were diagnosed as SCCs.
Conclusions: P63 IHC is useful for the identification of lung SCCs.
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Introduction
The arrival, approximately a decade ago, of global gene
expression profiling studies meant an improvement in the
classification of many malignant neoplasias [1]. However, the
practical impact on lung carcinoma classification has been
comparatively small [2]. In a previous microarray study, we
compared primary lung adenocarcinoma (AC) with squamous cell
carcinoma (SCC) in order to find new immunohistochemical
antibodies that could improve the accuracy of the distinction in
daily practice [3]. Our approach was very robust because cases
included in the analysis were surgical specimens re-classified by
two thoracic pathologists (EC and FL-R) according to the 2004
WHO Classification [4]. One of the top differentially expressed
genes that we found was P63, a well-known marker of squamous
differentiation but, surprisingly, its expression is not widely used
for this purpose in pathology laboratories worldwide. Indeed, this
result was validated with a tissue microarray (TMA) (Fig. 1 and
Table 1).
Nowadays we are facing a situation in which some new targeted
agents should not be used in SCCs, not only because they do not
provide better response rates (pemetrexed), but also because their
use in this histological type is associated with life-threatening
complications (i.e. bevacizumab) [5–7]. To further complicate the
field, other agents (i.e., anti-IGFR) might only (or preferably)
increase the response rate of SCC [8].
Given the recent need to identify lung SCCs, we tried to further
confirm our previous findings in another independent series. At
the same time, we sought to investigate the feasibility of this
approach to reduce the ‘‘large cell carcinoma (LCC)’’ category in
surgical specimens and to increase the number of specific
diagnoses in a prospective series of small thoracic samples.
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Methods
Ethics Statement
Written informed consent was obtained from all participants
involved. We obtained ethics approval from the ethics committees
at all institutions where samples were analyzed.
Tumor samples and histological characteristics
Small cell lung carcinomas were excluded from the study. Fig. 1
summarizes our methodology, including our published data [3].
To further confirm our P63 microarray data in another
independent cohort (second validation series), we started studying
146 patients who underwent resection of staged pI-II NSCLCs at
‘‘12 de Octubre’’ University Hospital between 1993 and 1997.
Pathological characteristics of the tumors included in the analysis
were as follows: 33 (23%) ACs; 99 (69%) SCCs; 10 (7%) LCCs and
four (3%) sarcomatoid carcinomas (SCs). This study was
performed on TMAs and only P63 IHC was performed. Next,
our aim was to investigate the utility of P63 and also TTF-1
immunostaining to reduce the number of LCC diagnoses on
surgically resected lung specimens. We included 231 patients
(reducing the ‘‘LCC’’ category series) who underwent resection of
staged pI-II NSCLCs at ‘‘12 de Octubre’’ University Hospital
between 1997 and 2003. Pathological characteristics of the tumors
included were as follows: 60 (26%) ACs; 151 (65%) SCCs; and
twenty (9%) LCCs. The study was performed on whole tissue
sections. Afterwards, we investigated the feasibility of the same
approach in a prospective cohort (reducing the ‘‘carcinoma NOS’’
category series) of 66 small thoracic samples (51 bronchoscopic
biopsies and fifteen core-needle biopsies) from the Targeted
Therapies Laboratory at the Madrid Sanchinarro University
Hospital. The classification of the tumors was as follows: 47 (71%)
carcinoma not otherwise specified (NOS); 13 (20%) ACs; and six
(9%) SCCs. Thirty two of the 47 undefined carcinomas (27
bronchoscopic biopsies and five core-needle biopsies) could be
further studied for P63 and TTF-1. In the remaining cases in this
group, all tissue had been previously used for mutation analysis
(data not shown). After clinical evaluation, all but two cases were
considered unresectable. In spite of not having the ‘‘gold
standard’’ of surgical excision, we chose to study this cohort
because it is precisely in patients with advanced lung carcinoma in
which our approach would be most helpful.
Figure 1. Summary of the methodology used in the different series. 1. See reference 3. 2. This series also included 10 large cell carcinomas
and 4 sarcomatoid carcinomas.
doi:10.1371/journal.pone.0012209.g001
Table 1. Validation of P63 IHC as a marker of squamous
differentiation.
1u IHC validation series# 2u IHC validation series
SCC (n = 29) AC (n = 39) SCC (n = 91*) AC (n = 29{)
P63 negative 7 (24%) 29 (74%) 42 (46%) 27 (93%)
P63 positive 22 (76%) 10 (26%) 49 (54%) 2 (7%)
P,0.001 P,0.001
#Published data (see reference 3).
*8 SCCs were not available for immunostaining evaluation.
{4 ACs were not available for immunostaining evaluation.
doi:10.1371/journal.pone.0012209.t001
Table 2. Re-classification of 20 Large cell carcinomas of the
lung by the staining pattern of P63.
Case Initial Diagnosis P63 IHC TTF-1 IHC Final Diagnosis
1 LCC Positive Positive SCC
2 LCC Negative Positive AC
3 LCC Positive Negative SCC
4 LCC Positive Negative SCC
5 LCC Negative Negative Neuroendocrine LCC{
6 LCC Negative Positive AC
7 LCC Positive Positive SCC
8 LCC Positive Negative SCC
9 LCC Negative Positive Neuroendocrine LCC{
10 LCC Positive Negative SCC
11 LCC Negative Positive AC
12 LCC Positive Negative SCC
13 LCC Positive Negative SCC
14 LCC Negative Positive AC
15 LCC Negative Negative Neuroendocrine LCC{
16 LCC Negative Positive AC
17 LCC Negative Positive AC
18 LCC Positive Negative SCC
19 LCC Negative Positive AC
20 LCC Positive Negative SCC
{Cases with neuroendocrine differentiation after histological review, confirmed
by neuroendocrine IHC markers (synaptophysin and CD56).
doi:10.1371/journal.pone.0012209.t002
P63 Immunohistochemistry
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Immunohistochemistry
We performed immunohistochemical (IHC) staining of P63
(4A4, 1:50 dilution; DAKO) in all cohorts. The anti-P63
monoclonal antibody 4A4 recognizes all 6 isoforms (total P63
expression): TAp63a, TAp63b, TAp63c, DNp63a, DNp63b,
DNp63c [9]. IHC staining of TTF-1 (8G7G3/1, 1:200; DAKO)
was also carried out in the last two series. After incubation,
immunodetection was done with the DAKO EnVision Visuali-
zation Method (Dako, Glostrup, Denmark), with diaminobenzi-
dine chromogen as the substrate. Sections were counterstained
with hematoxylin. Immunostaining was evaluated by two
different pathologists (EC and FL-R), using criteria based on
published cut-offs, as follows. P63: scored positive when high
intensity staining was present on $50% of tumor cells; the
remainder was scored negative [10]. TTF-1: scored positive when
staining was present on $5% of tumor cells; the remainder was
scored negative [11]. For both antibodies, only distinct and
intense nuclear staining was considered positive. For all LCCs
with neuroendocrine morphology, immunostaining for CD56
(123C3, 1:50 dilution; DAKO) and synaptophysin (SY38, 1:25
dilution; DAKO) also was performed to confirm neuroendocrine
differentiation.
Statistical analysis
Frequencies were compared either by Fisher’s exact test or by
the X2 contingency test. Differences of p,0.05 were considered
statistically significant. Analyses were performed using the SPSS
program, version 10.0.5 (SPSS Inc, Chicago, IL).
Figure 2. P63 and TTF-1 immunohistochemistry. Cases of LCC (A), carcinoma NOS on bronchoscopic biopsy (B) and carcinoma NOS on core-
needle biopsy (C) are shown. They were all re-classified as SCCs, showing a mutually exclusive pattern: P63 positive and TTF-1 negative. For both
antibodies only distinct nuclear staining was considered positive. High-intensity staining in $50% of tumor cells was scored as positive for P63.
doi:10.1371/journal.pone.0012209.g002
P63 Immunohistochemistry
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Results
Validation of P63 immunohistochemical expression as a
marker of squamous differentiation
Results of P63 expression are summarized in Table 1. In the
first validation series, sensitivity = 0.76, specificity = 0.74, positive
predictive value = 0.69, negative predictive value = 0.81 and
accuracy = 0.75. In the second validation series, two of 29 ACs
(7%) compared with 49 of 91 SCCs (54%) were positive for P63
IHC (p,0.001). Sensitivity, specificity, positive predictive value,
negative predictive value and accuracy were 0.54, 0.93, 0.96, 0.39
and 0.63, respectively.
Value of P63 and TTF-1 immunohistochemistry in
reducing the ‘‘large cell carcinoma’’ category in surgical
specimens
On the basis of our previous results of P63 IHC as a squamous
marker and the published data demonstrating that TTF-1 is
essentially not detected in SCCs, we assessed the utility of both
antibodies for re-classifying 20 LCCs (Table 2) [12,13]. Half of the
20 (50%) LCCs were positive for P63 and were re-classified as
SCCs. All but two P63 positive cases did not express TTF-1
(Fig. 2A). The remaining eight cases were positive for TTF-1 and
seven were considered ACs. Finally, three carcinomas exhibited
features of neuroendocrine differentiation (palisading, necrosis,
high mitotic rate, etc.) that was confirmed with IHC. They were
therefore termed ‘‘large cell neuroendocrine carcinomas’’. All
three were negative for P63, and two of them remained negative
for TTF-1.
Value of P63 and TTF-1 immunohistochemistry in
reducing the ‘‘carcinoma not otherwise specified (NOS)’’
category in small specimens
Results are summarized in Table 3. All P63 positive cases (11/
32, 34%) were diagnosed as SCCs (Fig. 2B and 2C) although two
of them co-expressed TTF-1. All P63 negative tumors were
considered ACs if they showed TTF-1 positivity (13/32, 41%), and
only ‘‘suggestive of AC’’ if this latter antibody was not available (5/
32, 16%). Finally, in three instances both antibodies were negative
(3/32, 9%), and subsequent follow-up was able to identify one
adenocarcinoma and one sarcomatoid carcinoma.
Discussion
We have shown the clinical utility of P63 IHC for the
identification of lung SCCs, further validating our previous
microarray study. That P63 is a marker of squamous differenti-
ation is well known and overexpression of this gene has been
consistently identified in lung SCCs by global gene expression
profiling or by IHC [14–20]. The reported positivity by this latter
method is usually over 80% in most series, but it should be
emphasized that better differentiated areas and even well-
differentiated tumors may be negative [10,12,18,21,22]. This fact
may explain the comparatively low rate of positivity in our two
validation series (Fig. 1 and Table 1) using TMAs (76% and 54%).
Fortunately, this is not a problem in clinical samples because IHC
is not needed in well differentiated SCC. Nonetheless, the
specificity of P63 IHC has been challenged. Although from 0%
to 33% of lung ACs may express P63, negative P63 IHC is used
when researchers need to accurately identify ACs for other
purposes [9,12,21,23–26]. These differences maybe explained by
variability at two phases of the procedure: (1) the antibody that
has been used to detect P63 (analytical phase), and (2) the
interpretation (post-analytical phase) of the staining. The first
possibility is less likely [27]. Although DNp63 isoforms are
frequently expressed in SCCs [28], most of the IHC studies of
P63 expression use antibodies that detect all P63 isoforms
(TAp63a, TAp63b, TAp63c, DNp63a, DNp63b, DNp63c)
[10,27,29,30]. In agreement with other authors, we believe that,
Table 3. Re-classification of 32 carcinomas (NOS) by the











1 Bronchoscopic Carcinoma Negative Negative Carcinoma1
2 Bronchoscopic Carcinoma Positive Negative SCC1
3 Bronchoscopic Carcinoma Positive Negative SCC2
4 Bronchoscopic Carcinoma Positive Negative SCC
5 Bronchoscopic Carcinoma Negative — Suggestive
of AC
6 Core-needle Carcinoma Positive Negative SCC1
7 Bronchoscopic Carcinoma Positive — SCC1
8 Bronchoscopic Carcinoma Positive Negative SCC1
9 Bronchoscopic Carcinoma Negative — Suggestive
of AC3
10 Bronchoscopic Carcinoma Positive — SCC1
11 Bronchoscopic Carcinoma Positive Negative SCC1
12 Bronchoscopic Carcinoma Negative — Suggestive
of AC
13 Bronchoscopic Carcinoma Negative Positive AC
14 Core-needle Carcinoma Negative Positive AC4
15 Bronchoscopic Carcinoma Negative Positive AC
16 Bronchoscopic Carcinoma Negative Positive AC5
17 Bronchoscopic Carcinoma Negative — Suggestive
of AC
18 Bronchoscopic Carcinoma Negative — Suggestive
of AC
19 Bronchoscopic Carcinoma Positive Positive SCC
20 Core-needle Carcinoma Negative Positive AC
21 Bronchoscopic Carcinoma Negative Positive AC3
22 Core-needle Carcinoma Negative Positive AC
23 Bronchoscopic Carcinoma Positive — SCC
24 Bronchoscopic Carcinoma Positive Positive SCC1
25 Bronchoscopic Carcinoma Negative Positive AC4
26 Bronchoscopic Carcinoma Negative Negative Carcinoma6
27 Bronchoscopic Carcinoma Negative Positive AC
28 Bronchoscopic Carcinoma Negative Negative Carcinoma7
29 Bronchoscopic Carcinoma Negative Positive AC
30 Core-needle Carcinoma Negative Positive AC
31 Bronchoscopic Carcinoma Negative Positive AC4
32 Bronchoscopic Carcinoma Negative Positive AC4
1KRAS and EGFR wild type tumour;
2Confirmed after surgical excision;
3Tumour with EGFR gene amplification;
4KRAS mutant tumours (G12C or G12V);
5EGFR mutant tumour (E746-A750del);
6Sarcomatoid carcinoma confirmed after surgical excision;
7AC confirmed in a subsequent pleural effusion.
doi:10.1371/journal.pone.0012209.t003
P63 Immunohistochemistry
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from a practical point of view, faint or focal immunostaining for
P63 should be considered non-specific until there is proof that it is
not [10]. Therefore, to increase the specificity of P63 IHC, we
considered a positive result when high intensity staining was
present in $50% of tumor cells [10]. Accordingly, some authors
have demonstrated that when using this approach, fewer ACs are
P63 positive [31]. Ang et al. have recently reported that P63
maybe positive (.20% tumor cells) or focal (#20% tumor cells) in
6% and 23% of ACs, respectively, whereas this tumor type
exhibits very rarely (1.6%) diffuse staining (.50% tumor cells)
[31].
Along these lines, several other approaches have been proposed
to improve the classification of lung carcinomas. Such procedures
include the use of a combination of markers (CD63, P63 and
CD56 or TTF-1, CK 5/6, and P63 or a five-antibody test
comprising TRIM29, CEACAM5, SLC7A5, MUC1, and CK5/
6), the use of novel antibodies (democollin-3) or even microRNA
expression [12,26,30,32,33]. Interestingly, the desmocollin-3
proposal was in fact derived from our microarray study (page
710 in reference 30), because this was indeed the top differentially
expressed gene [3]. We chose to validate P63, in spite of its lower
fold-change, because of the reproducibility of a nuclear staining
and the availability of the antibody (i.e. P63 IHC is routinely used
for assessing the in situ versus infiltrative nature of breast and
prostate carcinomas) [34–36]. Overall, the methodologies taken by
other researchers to raise specificity may also lower the likelihood
of clinical application because of the very limited material that is
usually obtained in bronchoscopic or core-needle biopsies.
Interestingly, another group has recently arrived at similar
conclusions although their specific data is not shown [37].
After we had validated our microarray data in two independent
series, we wanted to address two of the clinically relevant problems
in lung targeted therapies. Both surgically resected and unresect-
able biopsy-proven lung carcinomas with a non-specific diagnosis
(i.e., termed ‘‘LCC’’ in the former case and ‘‘carcinoma NOS’’ in
the latter) may eventually be considered for a targeted therapy that
must exclude SCCs. Assuming, based on our previous evidence,
that P63 positive cases are bona fide SCCs, we were able to
demonstrate the usefulness of P63 IHC in a series of surgically
resected LCCs and in a prospective cohort of small specimens.
One could argue that there is no ‘‘gold standard’’ in these two
situations, which is true, but this approach parallels the real
clinical work. The term ‘‘LCC’’ is defined as one of exclusion and,
as such, this category has been questioned. Indeed, in microarray
experiments these cases belong to either the AC or the SCC group
[20,38]. Therefore, the diagnosis of LCCs is not reproducible and
depends on several uncontrollable parameters (sampling, exper-
tise, etc.). On the other hand, in the real clinical world, we are
constantly asked to refine the ‘‘carcinoma NOS’’ group in order to
guide the oncologist’s therapeutic decision. In our setting, in over
70% of the biopsies of the unresectable lung carcinomas, neither
keratin nor gland formation were identified.
In summary, we have demonstrated how the use of P63 IHC
with rigid interpretation criteria can effectively improve the
identification of SCCs. Targeted therapies in the field of lung
cancer need more reproducible histological diagnoses.
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